Our top pick for
Building a portfolio
Anchiano Therapeutics Ltd is a biotechnology business based in the US. Anchiano Therapeutics shares (ANCN) are listed on the NASDAQ and all prices are listed in US Dollars. Anchiano Therapeutics employs 3 staff and has a market cap (total outstanding shares value) of USD0.00.
|52-week range||USD$11.20 - USD$94.40|
|50-day moving average||USD$61.36|
|200-day moving average||USD$34.74|
|Wall St. target price||USD$1.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-5.21|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$0|
|Return on assets TTM||-52.84%|
|Return on equity TTM||-125.6%|
|Market capitalisation||USD$34.9 million|
TTM: trailing 12 months
There are currently 65,165 Anchiano Therapeutics shares held short by investors – that's known as Anchiano Therapeutics's "short interest". This figure is 65.7% down from 190,175 last month.
There are a few different ways that this level of interest in shorting Anchiano Therapeutics shares can be evaluated.
Anchiano Therapeutics's "short interest ratio" (SIR) is the quantity of Anchiano Therapeutics shares currently shorted divided by the average quantity of Anchiano Therapeutics shares traded daily (recently around 3.3 million). Anchiano Therapeutics's SIR currently stands at 0.02. In other words for every 100,000 Anchiano Therapeutics shares traded daily on the market, roughly 20 shares are currently held short.
However Anchiano Therapeutics's short interest can also be evaluated against the total number of Anchiano Therapeutics shares, or, against the total number of tradable Anchiano Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Anchiano Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Anchiano Therapeutics shares in existence, roughly 10 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Anchiano Therapeutics shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Anchiano Therapeutics.
Find out more about how you can short Anchiano Therapeutics stock.
We're not expecting Anchiano Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Anchiano Therapeutics's shares have ranged in value from as little as $11.2002 up to $94.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Anchiano Therapeutics's is 0.9598. This would suggest that Anchiano Therapeutics's shares are less volatile than average (for this exchange).
Anchiano Therapeutics Ltd. , a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapeutics. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/ß-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/ß-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration and license agreement with ADT Pharmaceuticals, LLC to research and develop programs related to the pan-RAS and PDE10/ß-catenin programs. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd.
Steps to owning and managing TREB-U, with 24-hour and historical pricing before you buy.
Steps to owning and managing TIG, with 24-hour and historical pricing before you buy.
Steps to owning and managing TDAC, with 24-hour and historical pricing before you buy.
Steps to owning and managing TREB, with 24-hour and historical pricing before you buy.
Steps to owning and managing TREB-WS, with 24-hour and historical pricing before you buy.
Steps to owning and managing TDG, with 24-hour and historical pricing before you buy.
Steps to owning and managing TACT, with 24-hour and historical pricing before you buy.
Steps to owning and managing TT, with 24-hour and historical pricing before you buy.
Steps to owning and managing TROX, with 24-hour and historical pricing before you buy.
Steps to owning and managing TRVG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.